Jan Endrikat
Overview
Explore the profile of Jan Endrikat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Endrikat J, Ullmann A, Gerlinger C, Bhatti A, Lengsfeld P, Michel A
Br J Radiol
. 2024 Sep;
97(1164):2004-2014.
PMID: 39312632
Objective: To analyse the potential impact of patients' sex, race, and region/country on the risk of hypersensitivity reactions after intra-venous or intra-arterial administration of iopromide. Methods: Two analyses were performed....
2.
Endrikat J, Schmidt G, Oak B, Shukla V, Nangia P, Schleyer N, et al.
Patient Prefer Adherence
. 2024 Aug;
18:1577-1588.
PMID: 39100427
Purpose: Women with high breast density (HBD) carry an increased risk for breast cancer (BC). The aim of the study was to provide data on awareness and knowledge gaps among...
3.
Endrikat J, Gutberlet M, Hoffmann K, Schockel L, Bhatti A, Harz C, et al.
Invest Radiol
. 2024 Mar;
59(9):605-613.
PMID: 38426761
Background: The macrocyclic gadolinium-based contrast agent gadobutrol was introduced to the market in February 1998. Over the last 25 years, gadobutrol has been administered more than 100 million times worldwide...
4.
5.
Endrikat J, Gutberlet M, Barkhausen J, Schockel L, Bhatti A, Harz C, et al.
Invest Radiol
. 2023 Nov;
59(5):345-358.
PMID: 37972293
Background: Gadobutrol has been administered more than 100 million times worldwide, since February 1998, that is, over the last 25 years. Numerous clinical studies in a broad range of indications...
6.
Endrikat J, Khater H, Boreham A, Fritze S, Schwenke C, Bhatti A, et al.
Breast Cancer (Auckl)
. 2023 Aug;
17:11782234231189467.
PMID: 37600467
Background: Contrast-enhanced mammography (CEM) is an emerging breast imaging modality. Clinical data is scarce. Objectives: To summarize clinical evidence on the use of iopromide in CEM for the detection or...
7.
Endrikat J, Schmidt G, Haverstock D, Weber O, Trnkova Z, Barkhausen J
Breast Cancer (Auckl)
. 2022 Apr;
16:11782234221092155.
PMID: 35462754
Background: The impact of certain tumor parameters on the sensitivity of imaging tools is unknown. The purpose was to study the impact of breast cancer histology, tumor grading, single receptor...
8.
Schmidt G, Guhl M, Solomayer E, Wagenpfeil G, Hammadeh M, Juhasz-Boess I, et al.
Arch Gynecol Obstet
. 2022 Apr;
306(5):1689-1695.
PMID: 35377046
Background: PD-L1 receptor expression in breast cancer tissue can be assessed with different anti-human PD-L1 monoclonal antibodies. The performance of three specific monoclonal antibodies in a head-to-head comparison is unknown....
9.
Endrikat J, Chernova J, Gerlinger C, Pracz M, Lengsfeld P, Bhatti A, et al.
Invest Radiol
. 2021 Dec;
57(5):318-326.
PMID: 34860739
Purpose: The aim of this study was to analyze the risk of hypersensitivity reactions (HSRs) to iopromide in children and elderly patients in comparison to adults. Materials And Methods: Four...
10.
Liu B, Rosenberg M, Saverio P, Weon Y, Peters S, Ardellier F, et al.
AJR Am J Roentgenol
. 2021 Jun;
217(5):1195-1205.
PMID: 34133205
Gadobutrol and gadoterate are widely used macrocyclic gadolinium-based contrast agents. Given gadobutrol's higher T1 relaxivity, a reduced gadobutrol dose should achieve essentially equivalent diagnostic efficacy as a standard dose of...